COLO B Stock Overview
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Kerecis Acquisition To Transform Advanced Wound Care Segment
My Notes
Capture your thoughts, links and company narrative
Coloplast A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 835.80 |
| 52 Week High | DKK 977.60 |
| 52 Week Low | DKK 772.00 |
| Beta | 0.35 |
| 1 Month Change | 6.31% |
| 3 Month Change | -4.13% |
| 1 Year Change | 4.50% |
| 3 Year Change | -12.70% |
| 5 Year Change | -8.84% |
| Change since IPO | 6,441.05% |
Recent News & Updates
Coloplast A/S' (CPH:COLO B) Share Price Could Signal Some Risk
Jan 27
An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued
Jan 09Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Dec 04Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?
Nov 29Recent updates
Coloplast A/S' (CPH:COLO B) Share Price Could Signal Some Risk
Jan 27An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued
Jan 09Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Dec 04Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?
Nov 29Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 13Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Nov 08Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Oct 18Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 23Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?
Aug 22Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price
Jul 17These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jun 29Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations
May 21Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00
May 10Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report
May 09A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)
Apr 26There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price
Apr 08Is Coloplast (CPH:COLO B) A Risky Investment?
Mar 21Shareholder Returns
| COLO B | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | 2.3% | 0.9% | 2.4% |
| 1Y | 4.5% | 3.7% | -13.0% |
Return vs Industry: COLO B matched the Danish Medical Equipment industry which returned 3.7% over the past year.
Return vs Market: COLO B exceeded the Danish Market which returned -13% over the past year.
Price Volatility
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 3.1% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DK Market | 10.6% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: COLO B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: COLO B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 16,639 | Kristian Villumsen | www.coloplast.com |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Coloplast A/S Fundamentals Summary
| COLO B fundamental statistics | |
|---|---|
| Market cap | DKK 187.27b |
| Earnings (TTM) | DKK 5.05b |
| Revenue (TTM) | DKK 27.03b |
37.2x
P/E Ratio7.0x
P/S RatioIs COLO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLO B income statement (TTM) | |
|---|---|
| Revenue | DKK 27.03b |
| Cost of Revenue | DKK 8.76b |
| Gross Profit | DKK 18.27b |
| Other Expenses | DKK 13.22b |
| Earnings | DKK 5.05b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 22.44 |
| Gross Margin | 67.59% |
| Net Profit Margin | 18.69% |
| Debt/Equity Ratio | 120.6% |
How did COLO B perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield98%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 00:18 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Coloplast A/S is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Robert Bate | Barclays |
| Hassan Al-Wakeel | Barclays |